Australia’s Therapeutic Goods Administration (TGA) has reported laboratory testing failures in four unapproved peptide products marketed under the Synedica brand. Testing found no detectable TB-500 in three formulations and identified lower-than-declared retatrutide content with significant variation between samples. The findings emerged from the regulator’s cooperation with New South Wales Police in an investigation into the alleged illegal manufacture and distribution of peptide products. Laboratory testing reveals discrepancies in product composition According to the TGA safety advisory published on 5 November 2026, laboratory analysis identified discrepancies between product labels and the actual...